Literature DB >> 16432718

MRI growth patterns of plexiform neurofibromas in patients with neurofibromatosis type 1.

V F Mautner1, M Hartmann, L Kluwe, R E Friedrich, C Fünsterer.   

Abstract

Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder with an incidence of 1:3000. Approximately 30% of NF1 patients develop plexiform neurofibromas (PNF) which often cause severe clinical deficits. We studied the growth patterns of 256 plexiform neurofibromas (PNF) by magnetic resonance imaging (MRI) and associated disfigurement and functional deficits to determine whether there are definable growth types of these tumors. Retrospectively, we evaluated MRI scans obtained during 1997 to 2003 of 256 plexiform neurofibromas from 202 patients with NF1. Clinical investigation was carried out at the same time as the MRI scans. We identified three growth patterns: superficial in 59, displacing in 76, and invasive growth in 121 tumors. The majority (52%) of invasive PNF were found in the face, head and neck area. While superficial PNF primarily caused aesthetic problems, displacing PNF led in most cases to aesthetic problems and pain, while invasive PNF led mainly to functional deficits and disfigurement. Our study demonstrates that PNF have different growth patterns that are associated with specific clinical features. Classification of PNF may open new opportunities in clinical management, especially regarding decisions and options associated with surgical intervention.

Entities:  

Mesh:

Year:  2006        PMID: 16432718     DOI: 10.1007/s00234-005-0033-4

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  12 in total

Review 1.  The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2.

Authors:  D H Gutmann; A Aylsworth; J C Carey; B Korf; J Marks; R E Pyeritz; A Rubenstein; D Viskochil
Journal:  JAMA       Date:  1997-07-02       Impact factor: 56.272

2.  Magnetic resonance imaging of subcutaneous diffuse neurofibroma.

Authors:  W C Peh; T W Shek; D K Yip
Journal:  Br J Radiol       Date:  1997-11       Impact factor: 3.039

3.  Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales.

Authors:  S M Huson; P S Harper; D A Compston
Journal:  Brain       Date:  1988-12       Impact factor: 13.501

4.  MRI evaluation of superficial soft tissue lesions in children.

Authors:  A A Jabra; G A Taylor
Journal:  Pediatr Radiol       Date:  1993

5.  Spinal tumours in neurofibromatosis type 1: an MRI study of frequency, multiplicity and variety.

Authors:  S D Thakkar; U Feigen; V F Mautner
Journal:  Neuroradiology       Date:  1999-09       Impact factor: 2.804

Review 6.  Plexiform neurofibromas.

Authors:  B R Korf
Journal:  Am J Med Genet       Date:  1999-03-26

7.  Mortality in neurofibromatosis 1: an analysis using U.S. death certificates.

Authors:  S A Rasmussen; Q Yang; J M Friedman
Journal:  Am J Hum Genet       Date:  2001-03-28       Impact factor: 11.025

8.  Subtotal and total resection of superficial plexiform neurofibromas of face and neck: four case reports.

Authors:  Reinhard E Friedrich; Rainer Schmelzle; Melanie Hartmann; Victor-F Mautner
Journal:  J Craniomaxillofac Surg       Date:  2005-01-12       Impact factor: 2.078

9.  Growth type of plexiform neurofibromas in NF1 determined on magnetic resonance images.

Authors:  R E Friedrich; B Korf; C Fünsterer; V F Mautner
Journal:  Anticancer Res       Date:  2003 Mar-Apr       Impact factor: 2.480

10.  CT imaging in adults with neurofibromatosis-1: frequent asymptomatic plexiform lesions.

Authors:  J H Tonsgard; S M Kwak; M P Short; A H Dachman
Journal:  Neurology       Date:  1998-06       Impact factor: 9.910

View more
  24 in total

1.  Propranolol Specifically Suppresses the Viability of Tumorous Schwann Cells Derived from Plexiform Neurofibromas In Vitro.

Authors:  Ziang Zou; Linna Guo; Victor Mautner; Ralf Smeets; Lan Kiuwe; Reinhard E Friedrich
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

2.  Evaluation of intratumoural heterogeneity on ¹⁸F-FDG PET/CT for characterization of peripheral nerve sheath tumours in neurofibromatosis type 1.

Authors:  Johannes Salamon; Thorsten Derlin; Peter Bannas; Jasmin D Busch; Jochen Herrmann; Maximilian Bockhorn; Christian Hagel; Reinhard E Friedrich; Gerhard Adam; Victor F Mautner
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-12-12       Impact factor: 9.236

3.  PNist: interactive volumetric measurements of plexiform neurofibromas in MRI scans.

Authors:  Lior Weizman; Dina Helfer; Dafna Ben Bashat; Li-Tal Pratt; Leo Joskowicz; Shlomi Constantini; Ben Shofty; Liat Ben Sira
Journal:  Int J Comput Assist Radiol Surg       Date:  2013-11-20       Impact factor: 2.924

4.  Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours.

Authors:  Winfried Brenner; Reinhard E Friedrich; Karim A Gawad; Christian Hagel; Andreas von Deimling; Maike de Wit; Ralph Buchert; Malte Clausen; Victor F Mautner
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-01-11       Impact factor: 9.236

5.  Surgery for Peripheral Nerve Sheath Tumours of the Buttocks, Legs and Feet in 90 Patients With Neurofibromatosis Type 1.

Authors:  Reinhard E Friedrich; Caglayan T Tuzcu
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

6.  18F-FDG PET/CT for detection of malignant peripheral nerve sheath tumours in neurofibromatosis type 1: tumour-to-liver ratio is superior to an SUVmax cut-off.

Authors:  Johannes Salamon; Simon Veldhoen; Ivayla Apostolova; Peter Bannas; Jin Yamamura; Jochen Herrmann; Reinhard E Friedrich; Gerhard Adam; Victor F Mautner; Thorsten Derlin
Journal:  Eur Radiol       Date:  2013-10-05       Impact factor: 5.315

7.  Imatinib mesylate (Glivec) inhibits Schwann cell viability and reduces the size of human plexiform neurofibroma in a xenograft model.

Authors:  Maria Demestre; Jan Herzberg; Nikola Holtkamp; Christian Hagel; David Reuss; Reinhard E Friedrich; Lan Kluwe; Andreas Von Deimling; Victor-F Mautner; Andreas Kurtz
Journal:  J Neurooncol       Date:  2009-11-17       Impact factor: 4.130

8.  Benign whole body tumor volume is a risk factor for malignant peripheral nerve sheath tumors in neurofibromatosis type 1.

Authors:  Rosa Nguyen; Kimberly Jett; Gordon J Harris; Wenli Cai; Jan M Friedman; Victor-Felix Mautner
Journal:  J Neurooncol       Date:  2013-10-29       Impact factor: 4.130

9.  Safe marginal resection of atypical neurofibromas in neurofibromatosis type 1.

Authors:  Charlie N Nelson; Eva Dombi; Jared S Rosenblum; Markku M Miettinen; Tanya J Lehky; Patricia O Whitcomb; Christina Hayes; Gretchen Scott; Sarah Benzo; Brigitte C Widemann; Prashant Chittiboina
Journal:  J Neurosurg       Date:  2019-10-25       Impact factor: 5.115

10.  Efficacy and selectivity of nilotinib on NF1-associated tumors in vitro.

Authors:  Wei Jiang; Claudia Schnabel; Melanie Spyra; Victor-F Mautner; Reinhard E Friedrich; Christian Hagel; Paul W Manley; Lan Kluwe
Journal:  J Neurooncol       Date:  2013-10-31       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.